The prevalence of non-syndromic MVP has been estimated as 2.4% in the general population^[@R8]^. Family aggregation^[@R9],[@R10]^, presence in rare connective tissue syndromes^[@R11]^ as well as the identification of four linked loci^[@R2]--[@R5]^ indicate genetic heterogeneity for MVP. Additional factors such as age- and sex-dependent penetrance, with possible association with myocardial structural and functional abnormalities, suggest additional genetic complexity^[@R12]^. We conducted an initial discovery meta-analysis on two independent French genome-wide association studies (GWAS) including 1,412 MVP cases and 2,439 controls ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}), all of European ancestry, for \~4.8 million genotyped or imputed common (MAF \> 0.1) single nucleotide polymorphisms (SNPs) ([Supplementary Figure 1](#SD2){ref-type="supplementary-material"}). Three loci showed genome-wide (GW) significant associations with MVP (P \< 5×10^−8^) ([Table 1](#T1){ref-type="table"}). The strongest association (rs12465515; OR=1.33, *P*=1.08×10^−8^) was observed on Chr2q35 in a \~424 Kb gene-desert region where the nearest genes are *TNP1*, *IGFBP5* and *IGFBP2* (upstream) and *DIRC3* and *TNS1* (downstream) ([Table 1](#T1){ref-type="table"}). The two other GW-significant loci were at Chr17p13 (lead SNP rs216205, OR=1.35, P=3.02 × 10^−8^) in an intron of *SMG6* and at Chr22q12 near *MN1* and *PITPNB* (rs11705555 OR=1.34, P=4.47 × 10^−8^) ([Table 1](#T1){ref-type="table"}). We followed-up 23 loci with evidence of a suggestive association (P\<1×10^−5^) in a first replication panel that included European Americans and European Spanish cases and controls (Set 1 and Set 2, [Supplementary Figure 1](#SD2){ref-type="supplementary-material"}).

We genotyped or imputed a total of 47 SNPs (23 loci). An intermediate meta-analysis including the discovery and the follow-up Sets 1 and 2 (N~cases~= 2,312 and N~controls~=8,296) identified a subset of 24 SNPs (15 loci) with significant associations with MVP (P\<0.01), which were genotyped or imputed in two additional case-control studies from Canada and France (Sets 3 and Set 4, [Supplementary Figure 1](#SD2){ref-type="supplementary-material"}). In the global meta-analysis that included 2,864 cases and 9,218 controls, three additional loci associate with MVP at the genomic level ([Table 1](#T1){ref-type="table"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The overall strongest association was observed on Chr3p13 for rs171408 that maps in an intron of *LMCD1* (OR=1.32, *P* =1.29 × 10^−11^, [Table 1](#T1){ref-type="table"}). Two additional signals were identified on Chr21q22 near *CBR1* and *SETD4* (rs62229266, OR=1.22, *P*=1.18×10^−8^) and on Chr14q24 near *SIPA1L1* and *PCNX* (rs17767392, OR=1.23, *P* =2.27×10^−8^) ([Table 1](#T1){ref-type="table"}). We also confirmed the three GW-significant signals identified in the discovery samples with lead SNPs rs12465515 near *IGFB55* and *TNS1* (OR= 1.25, P =3.11×10^−11^), rs11705555 near *PITPNB* and *MN1* (OR=1.23, P=1.39×10^−8^) and rs216205 in *SMG6* (OR=1.24, P=1.46×10^−8^). Overall, we observed consistency in the direction of effects as well as nominal significant association in the follow-up meta-analysis and did not detect significant heterogeneity (P\>0.05) among case control studies ([Table 1](#T1){ref-type="table"}).

Many patients in the general population with MVP show few clinical symptoms, if any^[@R1]^. Nonetheless, a substantial subset of patients are at risk of heart failure and cardiac death, and MVP is the most common cause of isolated mitral regurgitation requiring surgical repair^[@R7]^. To investigate if the confirmed MVP risks alleles could be more prevalent among the more severely affected patients who required valve repair or replacement, we analysed the 1,680 French patients who underwent surgical intervention and compared them to 3,259 French controls ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). We did not find a stronger effect of any MVP risk alleles, except a slight increase in the frequency of the risk allele of rs11705555 at the *PITPNB*/MN1 locus (OR=1.31, 95%CI (1.19--1.44), P=1.88 × 10^−8^). Overall, our findings support that MVP is under significant genetic control with susceptibility loci of relatively homogeneous effect sizes (OR from 1.22 to 1.33).

MVP-associated loci implicate four intergenic (*IGFBP5*/*TNS1*, *SETD4*/*CBR1*, *PITBNB*/*MN1*, and *PCNX*/*SIPA1L1*) and two intronic (*LMCD1* and *SMG6*) regions. From an initial list of 53 genes (±500Kb to ±1Mb of the lead SNP), we identified candidate genes at each locus based on proximity to sentinel SNP, expression level in the heart, presence of eQTL signal in publically available databases (GTEX), proximity to previously identified GWAS signals for cardiovascular traits and a biological link with mitral valve or general cardiac development ([Supplementary Table 5](#SD1){ref-type="supplementary-material"} and [Supplementary Methods](#SD1){ref-type="supplementary-material"} for full details of gene prioritization strategy per locus).

We then investigated the expression pattern of candidate genes during valve development in mouse embryos by immunohistochemistry (IHC) at three time points that represent: *i*) completion of endothelial-to-mesenchymal transformation (EMT; E13.5), *ii*) valve sculpting and elongation (E17.5) and *iii*) achievement of the mature adult form (9 months old). Functional antibodies were only available for Tns1 and Igfbp5 on Chr2 and Pitpnb on Chr22. We also prioritized candidate genes in the MVP risk loci using morpholino knockdown (KD) based on the presence of clear zebrafish orthologs which, after filtering ([Supplementary note](#SD1){ref-type="supplementary-material"}), limited our analysis to eight genes at three loci: *igfbp2a*, *igfbp2b*, *igfbp5a*, *igfbp5b*, and *tns1* located at the chr2q35 locus; *lmcd1* at the chr3p13 locus and *smg6* and *sgsm2* at the chr17p13 locus.

On Chr2q35, rs12465515 lies within a large intergenic region with *TNS1 and IGFBP5* identified as the best two candidate genes ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). *TNS1* maps 750 kb downstream from the association signal at the chr2q35 locus ([Figure 2A](#F2){ref-type="fig"}). Tensin1, coded by *TNS1*, localizes to focal adhesions and interacts with actin, as does Filamin A, whose genetic variants can cause a rare X-linked form of MVP^[@R13]^. Tensin1 interacts with cytoplasmic tails of integrins to anchor stress fibers and plays an important role in metastatic capacities of cancer cells ^[@R14]^. On the other hand, *IGFBP5,* encoding insulin-like growth factor-binding protein 5 (IGFBP5), is known to modulate muscle differentiation and mediate high glucose-induced pro-fibrotic effects in cardiac fibroblasts^[@R15]^. IGFBP5 was also demonstrated to modulate migration and adhesion of cancer cells and could potentially be at play in valve development and valvular interstitial cell integrity.

Only faint nonspecific staining was observed for *Igfbp5* in valves of developing and adult mice ([Supplementary Figure 2](#SD2){ref-type="supplementary-material"}). In contrast, murine IHC data showed a sustained expression for Tensin1 during valve morphogenesis, being stronger along the atrialis aspect of the forming leaflet ([Figure 3A](#F3){ref-type="fig"}). We also found that Tensin1 expression is maintained during adulthood and localized in the endothelial and valvular interstitial cells ([Figure 3A](#F3){ref-type="fig"}). Hematoxylin and eosin (H&E) histological staining in 9-month old Tensin1^−/−^ mice showed enlarged posterior mitral leaflets compared to wild-type littermates ([Figure 3B](#F3){ref-type="fig"}). In addition, valves from *tns1*−/− mouse showed evidence of myxomatous degeneration, indicated by increased proteoglycan content and loss of normal matrix stratification as indicate the accumulation of proteoglycan in the valves ([Figure 3C](#F3){ref-type="fig"}). Preliminary echographic exploration of Tns1^−/−^ mice (n=2) showed slight leaflet displacement (0.4 mm) compared to wildtype (0.1 mm) consistent with larger leaflets but no mitral regurgitation ([Supplementary Figure 3](#SD2){ref-type="supplementary-material"}), indicating subtle anomalies of the mitral valve that deserve future confirmation. In zebrafish experiments, a significant increase in AV regurgitation incidence was observed in *tns1* knockdown for both morpholinos (3- and 1.1-fold increase, respectively; P=0.02 and P=0.01) ([Supplementary Video 2](#SD2){ref-type="supplementary-material"}) but not in simultaneous knockdown of both *igfbp2* and *igfbp5* isoforms ([Figure 2C](#F2){ref-type="fig"}). In situ hybridization identified high *tns1* expression throughout the developing heart, and knockdown diminished the aggregation of endothelial cells at the developing valve ([Supplementary Figure 4](#SD2){ref-type="supplementary-material"}). Further, although *notch1b* expression remained normally localized to the developing valve, the distribution of the valve development marker *bmp4* was highly disorganized ([Supplementary Figure 5](#SD2){ref-type="supplementary-material"}). Together, these results support Tensin 1 as the best candidate at the Chr2q35 locus for MVP pathogenesis.

The association signal at the Chr3p13 is intronic to *LMCD1.* Also named Dyxin, LMCD1 is a member of the LIM domain family of zinc finger proteins that act as co-regulators of transcription. It is highly expressed in mouse cardiac tissue and was demonstrated to be a direct repressor of GATA6, an important regulator of cardiac development^[@R6]^. Somatic mutations in *LMCD1* were described as potential oncogenic events in hepatocellular carcinoma metastasis by promoting cell migration^[@R16]^. The zebrafish knockdown of *lmcd1* results in significantly increased AV regurgitation for both morpholinos (4.7 and 1.2 fold increase in AV regurgitation; P=0.001 and P=0.009) ([Figure 4C](#F4){ref-type="fig"}, [Supplementary Video 3](#SD2){ref-type="supplementary-material"}). In addition, morphological analysis of the developing myocardium revealed *lmcd1* morphants exhibited a moderate reduction in cardiac looping ([Supplementary Video 3](#SD2){ref-type="supplementary-material"}). However, although *lmcd1* is expressed throughout the heart, after *lmcd1* knockdown, expression patterns of valve development markers *notch1b* and *bmp4* displayed no abnormalities ([Supplementary Figure 5](#SD2){ref-type="supplementary-material"}) and no mis-localization of endothelial cell aggregation was observed ([Supplementary Figure 4](#SD2){ref-type="supplementary-material"}). Further investigation will be required to determine if the AV regurgitation is due to a primary valve defect or a more general defect in cardiac development. Previous *in vitro* and *in vivo* studies showed that Lmcd1/Dyxin augment calcineurin^[@R17]^. Calcineurin signalling is required for AV endocardium EMT and subsequent valve morphogenesis in zebrafish^[@R18]^. rs355134, a highly correlated variant to the top SNP rs171408 (r^2^=0.84 according to 1000 genomes data), is located in a predicted myocyte enhancer factor 2A (MEF2A) binding site, a key transcription factor in cardiac development^[@R19]^. We have previously shown that Mef2C regulated matrix production in mouse valves^[@R20]^. Our data extend the role of LMCD1 to valve development, and the putative implication of LMCD1 in matrix production regulated by MEF2A deserves future investigation.

Amongst the remaining MVP loci, we detected expression for *Pitpnb*, candidate gene on Chr22q12, in valve endothelial and interstitial cells within the mouse mitral leaflets at each of the time points investigated ([Supplementary Figure 6](#SD2){ref-type="supplementary-material"}). At the Chr17p13 locus, knockdown of candidate genes included smg6 and sgsm2, neither of which led to a valvular phenotype in the zebrafish ([Supplementary Figure 7](#SD2){ref-type="supplementary-material"}). Additional candidate genes need to be explored at this locus, which has been associated with aortic root size^[@R21]^ and coronary heart disease^[@R19]^.

Despite the widespread prevalence, the molecular basis of MVP has largely been elusive. The first molecular pathways implicated in MVP arose from the observation of the disease in patients with Marfan or Ehlers-Danlos syndromes, findings that highlight the importance of extracellular matrix composition^[@R22]^, the TGF-beta growth factor pathway^[@R12],[@R23]^ and valve cell proliferation and differentiation^[@R24]^. Several structural mechanisms have also been proposed, such as enlargement and flattening of the mitral annulus^[@R25]^ that can impose additional stresses on genetically susceptible valves and chordae^[@R26]^. This first GWAS of non-syndromic MVP reveals several susceptibility loci supporting the concept that genetic variants affecting the expression of proteins during valve development can progressively affect mitral valve function into adult life, as was recently shown for Filamin-A^[@R27]^. In particular, we provide genetic and functional evidence that *TNS1* and *LMCD1* both implicated in cell proliferation and migration are contributing to mitral valve degeneration possibly during valve development, thus revealing new pathways as possible innovative therapeutic targets.

Online methods {#S1}
==============

Leducq Transatlantic MITRAL Network {#S2}
-----------------------------------

The majority of patients were recruited as a major project of the *Leducq Mitral* Network, a transatlantic consortium investigating the physiopathology of mitral valve disease with basic and clinical investigators from 10 clinical and research centres. Six centres recruited MVP patients, MVP-Nantes and MVP-France for the initial GWAS effort, MVP-USA, Framingham Heart Study (FHS) and PROlapso Mitral en cEntros eSpAñoles (PROMESA) at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) for initial replication and HEGP-Surgical Cases with QCCMRC data-sets in the last replication stage. Cases were compared with controls (Framingham Heart Study, PROMESA-CNIC and QCCMRC) or general population (D.E.S.I.R for initial GWAS and one replication stage), SU.VI.MAX (GWAS) ([Supplementary Figure 1](#SD2){ref-type="supplementary-material"}).

Cases recruitment criteria {#S3}
--------------------------

We used consensus inclusion criteria of adult (≥ 18 years) patients with idiopathic MVP if they presented displacement into the left atrium of any part of the mitral valve leaflet(s) ≥ 2 mm beyond a line connecting the annular hinge points on the parasternal long-axis view of the left ventricle by two-dimensional (2D) echocardiography^[@R1],[@R2]^. We also included patients with previous surgery for pure severe MR due to MVP supported by an operative report and written confirmation of the diagnosis by the surgeon (MVP-France, MVP-Nantes and Surgery Cases). All cases were validated by a local, experienced team of cardiologists on the basis of clinical and echocardiography records. Recruitments excluded patients with MVP associated with other heart disease (coronary artery disease with papillary muscle disruption, hypertrophic cardiomyopathy or rheumatic disease) or known syndromes (e.g. Marfan and Ehlers-Danlos). Local ethics committees approved all studies and all patients and controls provided written informed consent. Recruitment procedures of DNA collection are detailed per cohort in [Supplementary Note](#SD2){ref-type="supplementary-material"}.

Analytical methods {#S4}
------------------

### GWAS genotyping and quality control {#S5}

Genotyping of the discovery cohorts was independently performed by different genetic platforms that included standard quality control measures of genotyping and data acquisition from diverse high-density genotyping arrays ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). We excluded participants with genotype call rate \< 97% and individual heterozygosity (IHe) level \< 10,000 (determined as outlier limit after visual inspection). We excluded SNPs with a minor allele frequency (MAF) \<0.1, call rate \<95%, monomorphic, and with an exact Hardy Weinberg Equilibrium (HWE) p \< 0.0001 in controls and p \< 10^−7^ in demographically homogenous cases to exclude SNPs that show very large deviations.

### Imputation {#S6}

To complement directly genotyped SNPs we performed large-scale imputation in the four discovery cohorts. First, genotyped SNPs in cases and controls were phased using the SHAPE-IT (v1) program^[@R3]^. Then, the imputation of 4.8 million common SNPs (MAF\>0.1 in 1000G Europeans, proper-info \> 0.4) was carried out using IMPUTE v2^[@R4]^ in \~7 Mb chunks. The reference panel used was Phase I integrated variant set release (v3), in NCBI build 37 (hg19). We used similar procedures to impute non-genotyped SNPs in the replication cohort FHS using MACH software (0.3 r2_hat)^[@R5]^.

### Direct genotyping in the replication sets {#S7}

MGH cases from the follow-up Set1 and all cases and controls of Set2 were genotyped at the Massachusetts General Hospital PNGU Core Lab using the Sequenom iPLEX Gold^®^ application and MassARRAY^®^ system. Follow-up Sets 3 and 4 were genotyped at the LGC genomics company using the KASP^®^ genotyping chemistry. We excluded 9 individuals that failed genotyping for all SNPs, and SNPs with call rate \<0.90. No SNP deviated from HWE (P\>0.05).

### Demographic analyses {#S8}

The ancestry of participants was assessed using a multi-dimensional scaling technique implemented in PLINK^[@R6]^. SNPs were selected for short-range linkage disequilibrium (LD) independence (r^2^ \> 0.2). Multi-dimensional scaling method was applied on the Identity-By-State matrix and we excluded outliers on the first two components ([Supplementary Figure 8](#SD2){ref-type="supplementary-material"}) using an expectation-maximization (EM)-fitted Gaussian mixture clustering method implemented in the R package M-CLUST, assuming one cluster and noise ([Supplementary Note](#SD2){ref-type="supplementary-material"}).

Statistical Analyses {#S9}
--------------------

### Genome-wide and replication association with MVP status {#S10}

We applied a logistic regression (additive model) as implemented in SNPTEST^[@R4]^ to test the association with MVP in the GWAS discovery adjusted for the five first principal components as covariates. We also used SNPTEST and/or logistic regression on allele dosage in replication sets when cases and/or controls were imputed for genotypes (FHS in Set 1 and D.E.S.I.R. 2 in Set 4, [Supplementary Figure 1](#SD2){ref-type="supplementary-material"}) and took into account for relatedness among (FHS). For directly genotyped cases control studies (Set 2 and Set 3) we used logistic regression as implemented in PLINK.

For the GWAS meta-analysis, we applied the inverse normal strategy^[@R7]^. Because the number of controls greatly exceeds the number of cases in all studies, we used the effective sample size as advised in the METAL software ^[@R8]^:W= 4/(1/N~cases~+1/N~controls~).

Regional association plots for Chr2q35, Chr3p13 and Chr17p13 were created using Locus Zoom^[@R9]^.

Protein detection in mouse embryos and adult hearts {#S11}
---------------------------------------------------

Standard histological and immunochemical procedures were used as previously described^[@R10]^. For all immunohistochemistry (IHC) experiments, 5-min antigen retrieval was performed with VectaStain and Pressure Cooker (Cuisinart). Antibodies used for immunological experiments were: Tensin1 (Novus), MF20 (Developmental Hybridoma Banks). Primary antibodies were used for IHC at a 1:100 dilution, Hoescht 33342 (nuclear stain) was used at a 1:10,000 dilution. Appropriate secondary antibodies were used for detection.

Histology and expression studies were performed on adult (9-month) wild-type (*Tensin1^+/+^*) and knockout (*Tensin1^−/−^*) hearts. For Histology: Adult (9-month) hearts were processed for hematoxylin and eosin stainings and immunohistochemistry (IHC) as previously described ^[@R11]^. For all analyses male mice were used and N=3 for each genotype. Antibodies used for IHC were: Hyaluronan Binding Protein (HABP) to stain proteoglycans (1:100) (Callbiochem), collagen I (1:100) (MDbio), and Hoescht to stain nuclei (1:10,000) (Invitrogen).

Zebrafish experiments {#S12}
---------------------

Zebrafish experiments were performed in accordance with approved Institutional Animal Care and Use Committee (IACUC) protocols. TuAB zebrafish strains were reared according to standard techniques. Minimal effective doses of antisense morpholino oligonucleotides were injected at the single cell stage and compared to non-targeting morpholino injected controls. Nucleotides sequences are indicated in [Supplementary Table 6](#SD1){ref-type="supplementary-material"}. Embryos were scored for presence of AV regurgitation at 72 hours post-fertilization (hpf) using high speed videography. Semiquantitative PCR was used to demonstrate morpholino knockdown efficacy ([Supplementary Figure 9](#SD2){ref-type="supplementary-material"}). In situ hybridizations for tissue specific expression of lmcd1, tns1, bmp4, and notch1b were performed as described^[@R12]^. In order to visualize the localization of the developing cardiac cushions, flk-EGFP reporter fish were microinjected with anti-tns1 or anti-lmcd1 morpholinos. After manual excision of the heart at 72hpf, hearts were counterstained with rhodamine labelled phalloidin and mounted using Vectashield. Confocal micrographs were acquired on a Zeiss 510 LSM with a 20X air lens. Final Images represent 2D projections of a z-series (ImageJ).

Supplementary Material {#S13}
======================

###### 

Supplementary Table 1. Clinical and genotyping features of the study populations.

**Supplementary Table 2. Association with MVP of loci carried for follow-up and genotyped in all the study populations (N=13 loci).** One best-associated SNP is indicated per locus. Alleles are indexed to the forward strand of NCBI Build 37; P-values reported are two-sided and based on an inverse-variance weighted meta-analysis model (fixed-effects). P-values are for heterogeneity test between all individual studies (Cochran Q statistics); \*: OR and p values in the global met-analysis are indicated for the proxy genotyped in the follow-up.

Supplementary Table 3. Associations with MVP among surgery patients.

**Supplementary Table 4. Short literature descriptive of candidate genes near MVP confirmed loci.** References are listed in Supplementary note.

Supplementary Table 5. Initial list of genes for candidates prioritization for zebrafish knockdown.

**Supplementary Table 6. Nucleotide sequences used for morpholinos and morpholino efficacy 72 hours post fertilization (hpf).** \* E(X)I(X) indicates the exon and intron border which the morpholino targets.

###### 

**Supplementary Figure 1**. Study design with cohorts in discovery and follow-up and filtration strategy of SNPs.

**Supplementary Figure 2. Igfbp5 expression in mouse developing heart**. Cardiac expression of Igfbp5 (red) was analysed at embryonic (E13.5), foetal (E17.5) and adult time points. At all time points investigated very little Igfbp5 protein was detected in the valves. Expression was observed in the myocardium of the left and right atria as well and the primary atrial septum (PAS) at E13.5 and E17.5 (arrows) as well as the coronary endothelium in the adult (arrow heads). AL, PL, IVS, LV= anterior and posterior mitral leaflets, interventricular septum, and left ventricle, respectively. Green=MF20 (sarcomeric myosin-myocytes), Blue= hoescht (nuclei)

**Supplementary Figure 3. In vivo assessment of mitral valve phenotypes in Tns1 total knockout mice using echocardiographs.** Tensin1^+/+^: wildtype; Tensin1^−/−^: Tns1 knockout mice. Images were obtained in a four-chamber view of the heart.

**Supplementary Figure 4. In situ hybridizations of *tns1* and *lmcd1* mRNA distribution in zebrafish embryos**. Top panel: tns1 expression pattern at 96 hours post fertilization. Expression found throughout the myocardium with highest levels in the outflow tract (right). Lower panel: lmcd1 expression at 72 hours post fertilization. Expression is found in the entire myocardium with enhanced expression in the ventricular chamber.

**Supplementary Figure 5. In situ hybridizations for developmental markers of valvulogenesis *lmcd1* and *tns* knockdown embryos.** Top panel: anti-notch1b probe labels the developing valve in 72 hours post fertilization embryos. Lower panel: anti-*bmp-4* probe labels the valve and surrounding myocardium in control (CN) and *lmcd1* knockdown embryos. Arrows in both panels point to the approximate location of the AV valve.

**Supplementary Figure 6. Pitpnb expression in mouse developing heart.** Cardiac expression of Pitpnb (red) was analysed at embryonic (E13.5), foetal (E17.5) and adult time points. Pitpnb was detected in valve endothelial and interstitial cells within the mitral leaflets at each of the time points investigated. Expression was also observed in the epicardium (arrow head) and coronary endothelium (arrow) at E17.5. AL, PL, IVS, LV= anterior and posterior mitral leaflets, interventricular septum, and left ventricle, respectively. Green=MF20 (sarcomeric myosin-myocytes), Blue= hoescht (nuclei)

**Supplementary Figure 7. Assessment of cardiac regurgitation in zebrafish morpholino knockdown for genes on Chr17p13. a) Genomic context of the association signal observed in the GWAS meta-analysis. b) Morpholino-mediated knockdown efficacy**. Efficacy for *smg6* and *sgsm2* in embryonic zebrafish was measured by RT-PCR. **c) Fold change in observed mitral regurgitation in 72 hpf zebrafish embryos after morpholino mediated knockdown**. All results are relative to clutchmate controls. n=number of biological replicates per morpholino. **d) Brightfield micrographs displaying gross morphology of 72hpf embryos following *smg6* or *sgsm2* knockdown.** Scale bar represents 1mm. CN=control morpholino injected embryos.

**Supplementary Figure 8. Multidimensional scale-based principal component analysis.** Cases and controls positions on first and second components axis are presented for the two discovery samples (GWAS 1 and GWAS 2). C1: first principal component. C2: second principal component. *All individuals plotted are those included in the discovery GWAS who are all French with European ancestry origin. Cases and controls with non-European ancestry based on the principal component analyses were excluded before association tests.*

**Supplementary Figure 9: Representative gel images from analysis of morpholino efficacy.** rsID indicates the sentinel SNP at the analyzed locus. CN indicates samples amplified from control injected embryos whereas MO indicates amplicons from samples obtained following microinjection of gene-specific morpholino. All samples were obtained from 72 hours post fertilization embryos.
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![Quantile-quantile (A) and manhattan (B) plots representing the association of 4.8 million SNPs at the GWAS meta-analysis\
Red line indicates genome-wide significant threshold (P \< 5 × 10^−8^) and blue line the p-value thershold used for follow-up (P \< 10^−5^).](nihms711882f1){#F1}

![Cardiac regurgitation in zebrafish morpholino knockdown for candidate genes on Chr2q35\
**a) Genomic context of the association signal observed in the GWAS meta-analysis**. The regional association plot was generated using locus zoom and displays surrounding genes, with TNS1, IGFBP2 and IGFBP5 identified as best potential candidates at this locus. **b) Mitral regurgitation observed at 72 hours post fertilization (hpf) in zebrafish embryos after morpholino mediated knockdown**. All results are presented as fold change compared to clutchmate controls. n=number of biological replicates per morpholino. (\*) indicates p\<0.05. **c) 2-dimensional projections of z-series image stacks taken on excised control (CN) and *tns1* knockdown zebrafish hearts**. Green denotes EGFP expression, a marker of endothelium under the control of the *flk* promoter. Red staining indicates the distribution of F-actin, which is highly expressed in the functional myocardium. Scale bar represents 50μm. **d) anti-*bmp-4* probe labels the valve and surrounding myocardium in CN and *tns1* knockdown embryos**. Scale bar represents 50μm. **e) Brightfield micrographs displaying gross morphology of 72hpf zebrafish morphants**. Scale bar represents 1mm. Body axis length of morpholino-injected fish is slightly reduced compared to wild-types.](nihms711882f2){#F2}

![Murine Tensin 1 expression during developing valves and knockout phenotype at 9 months\
**A) Tensin1 expression in the mouse developing heart.** IHC was performed for Tensin1 (red) at E13.5 (complete epithelial mesenchymal transformation), E17.5 (valve sculpting and elongation) and 9 months of age. MF20 (green) labels myocytes, Hoescht (Blue) labels nuclei. (**B) Tensin1 knockout mice exhibit enlarged mitral leaflets.** Hematoxylin and Eosin (H&E) histological staining was performed on Wild-type (Tensin^+/+^) and Tensin knockout (Tensin1^−/−^) mice. Scale bars are denoted. **(C) Tensin1 knockout mice exhibit myxomatous mitral leaflets.** Immunohistochemistry (IHC) for collagen (red), proteoglycans (green) show failure of normal matrix stratification and expansion of proteoglycan expression in the tensin1−/− mitral leaflets indicative of a myxomatous phenotype. AL= Anterior Leaflet, PL= Posterior Leaflet, LV=Left Ventricle, IVS=interventricular septum. Scale bars are denoted.](nihms711882f3){#F3}

![Cardiac regurgitation in zebrafish morpholino knockdown for Lmcd1 on Chr3p13\
**a) Genomic context of the association signal observed in the GWAS meta-analysis.** The regional association plot was generated using locus zoom and displays surrounding genes, with *LMCD1* identified as best potential candidate as the signal is intronic to *LMCD1*. **b) Mitral regurgitation observed at 72 hours post fertilization (hpf) in zebrafish embryos after morpholino mediated knockdown**. All results are presented as fold change compared to clutchmate controls. n=number of biological replicates per morpholino. (\*) indicates p\<0.05.\
**c) 2-dimensional projections of z-series image stacks taken on excised 72hpf control (CN) and *lmcd1* knockdown zebrafish hearts**. Green denotes EGFP expression, a marker of endothelium under the control of the *flk* promoter. Red staining indicates the distribution of F-actin, which is highly expressed in the functional myocardium. Scale bar represents 50μm. **d) Brightfield micrographs displaying gross morphology of 72hpf embryos following *lmcd1* knockdown**. Scale bar represents 1mm. CN=control morpholino injected embryos. No detectable morphological difference is observed between morpholino-injected fish and wild-types.](nihms711882f4){#F4}

###### Genome-wide significant associations of single nucleotide polymorphisms with mitral valve prolapse

OR: odds ratio; 95%CI: 95% confidence interval; CC: case control. Locus designed for nearest or the best candidate gene. RA: risk allele. Alleles are indexed to the forward strand of NCBI Build 37. P-values reported are two-sided and based on an inverse-variance weighted meta-analysis model (fixed effects). P-value for heterogeneity corresponds to Cochran Q statistics.

  -------------- ---------------- ------------------ -------------- ------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ----------------------- --
  **2**          **rs12465515**   **IGFBP5/TNS1**    C              0.34    1.39 (1.23--1.56)   1.22 (1.03--1.45)   1.33 (1.2--1.47)    1.28 (1.14--1.47)   1.11 (0.84--1.47)   0.87 (0.57--1.33)   1.12 (0.95--1.33)   1.19 (1.09--1.32)   **1.25 (1.18--1.33)**   
  8.0 × 10^−8^   0.019            1.2 × 10^−8^       1.2 × 10^−4^   0.451   0.521               0.158               1.6 × 10^−4^        **3.1 × 10^−11^**   0.145                                                                                                   
  **3**          **rs171408**     **LMCD1**          G              0.22    1.41 (1.22--1.61)   1.14 (0.93--1.39)   1.3 (1.16--1.47)    1.19 (1.02--1.37)   1.64 (1.19--2.27)   1.18 (0.76--1.82)   1.52 (1.25--1.85)   1.32 (1.19--1.47)   **1.32 (1.22--1.43)**   
  3.0× 10^−6^    0.188            5.4 × 10^−6^       0.023          0.002   0.464               3.6 × 10^−5^        3.7 × 10^−7^        **1.3 × 10^−11^**   0.108                                                                                                   
  **14**         **rs17767392**   **PCNX/SIPA1L1**   T              0.25    1.33 (1.16--1.52)   1.12 (0.93--1.35)   1.26 (1.13--1.4)    1.19 (1.04--1.37)   1.04 (0.76--1.41)   1.2 (0.77--1.89)    1.32 (1.09--1.56)   1.20 (1.10--1.33)   **1.23 (1.15--1.32)**   
  2.0 × 10^−5^   0.224            3.1 × 10^−5^       0.009          0.814   0.424               0.004               1.7 × 10^−4^        **2.3 × 10^−8^**    0.522                                                                                                   
  **17**         **rs216205**     **SMG6**           T              0.74    1.41 (1.24--1.61)   1.25 (1.04--1.5)    1.35 (1.22--1.5)    1.15 (1.00--1.33)   1.06 (0.79--1.43)   1.22 (0.80--1.86)   1.15 (0.95--1.38)   1.15 (1.03--1.27)   **1.24 (1.15--1.33)**   
  3.0 × 10^−7^   0.018            3.0 × 10^−8^       0.044          0.697   0.364               0.141               0.009               **1.5 × 10^−8^**    0.273                                                                                                   
  **21**         **rs62229266**   **SETD4/CBR1**     T              0.36    1.19 (1.05--1.35)   1.37 (1.16--1.64)   1.25 (1.13--1.38)   1.35 (1.18--1.54)   1.15 (0.88--1.52)   0.86 (0.57--1.30)   1.04 (0.88--1.23)   1.19 (1.08--1.3)    **1.22 (1.14--1.30)**   
  0.005          1.7 × 10^−4^     8.2 × 10^−6^       2.3 × 10^−5^   0.303   0.469               0.605               2.6 × 10^−4^        **1.2 × 10^−8^**    0.066                                                                                                   
  **22**         **rs11705555**   **PITPNB/MN1**     C              0.26    1.32 (1.16--1.49)   1.37 (1.15--1.64)   1.34 (1.21--1.49)   1.16 (1.01--1.35)   1.09 (0.81--1.45)   0.91 (0.58--1.41)   1.19 (0.99--1.41)   1.15 (1.04--1.27)   **1.23 (1.15--1.33)**   
  2.8 × 10^−5^   4.0 × 10^−4^     4.5 × 10^−8^       0.032          0.594   0.657               0.059               0.007               **1.4 × 10^−8^**    0.313                                                                                                   
  -------------- ---------------- ------------------ -------------- ------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ----------------------- --
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